Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics (IPSC)
NASDAQ:IPSC
IPSC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.34 - $2.05
Previous CloseN/A
Volume712.78K
Average Volume (3M)924.78K
Market Cap
$47.39M
Enterprise Value-$56.18M
Total Cash (Recent Filing)$165.12M
Total Debt (Recent Filing)$52.67M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Nov 06, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding86,158,760
10 Day Avg. Volume683,170
30 Day Avg. Volume924,778
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.19
Enterprise Value/Revenue-0.49
Enterprise Value/Gross Profit-0.49
Enterprise Value/Ebitda6.08
Forecast
1Y Price Target
$3.75Price Target Upside569.64% Upside
Rating ConsensusHold
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressCentury expects to report initial data from the CALiPSO-1 trial by year-end, indicating progress in its clinical trials.
Financial StabilityThe company's cash runway has been extended into the fourth quarter of 2027, providing financial stability for future operations.
Innovative Platform DevelopmentAnalyst views the early preclinical data from the αβ iT platform as intriguing and believes clinical proof of concept from a functional iPSC-derived αβ iT candidate could be transformational for the company and the broader cell therapy space.
Bears Say
Financial ConstraintsCentury's cash runway is only into the fourth quarter of the following year, which could limit investment in the company's innovative platform.
Interpretability RisksSeveral factors, such as diverse autoimmune indications and geographic diversity, could reduce the interpretability of the first CNTY-101 data read-out.
Price Target ReductionThe price target for Century Therapeutics was reduced due to a decrease in the peer group valuation component.
Century Therapeutics News
IPSC FAQ
What was Century Therapeutics’s price range in the past 12 months?
Century Therapeutics lowest stock price was $0.34 and its highest was $2.05 in the past 12 months.
What is Century Therapeutics’s market cap?
Century Therapeutics’s market cap is $47.39M.
When is Century Therapeutics’s upcoming earnings report date?
Century Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 82 days.
How were Century Therapeutics’s earnings last quarter?
Century Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.376 by -$0.004.
Is Century Therapeutics overvalued?
According to Wall Street analysts Century Therapeutics’s price is currently Undervalued.
Does Century Therapeutics pay dividends?
Century Therapeutics does not currently pay dividends.
What is Century Therapeutics’s EPS estimate?
Century Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Century Therapeutics have?
Century Therapeutics has 86,158,760 shares outstanding.
What happened to Century Therapeutics’s price movement after its last earnings report?
Century Therapeutics reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.376. Following the earnings report the stock price went up 3.774%.
Which hedge fund is a major shareholder of Century Therapeutics?
Currently, no hedge funds are holding shares in IPSC
Century Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.75 (569.64% Upside)
$3.75 (569.64% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 241.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 12.7%
Last 30 Days ▲ 12.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.20%
12-Months-Change
Fundamentals
Return on Equity
-10.78%
Trailing 12-Months
Asset Growth
-31.64%
Trailing 12-Months
Company Description
Century Therapeutics
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPSC Stock 12 Month Forecast
Average Price Target
$3.75
▲(569.64% Upside)
Technical Analysis
Ownership Overview
3.65% Insiders
5.71% Mutual Funds
18.47% Other Institutional Investors
69.24% Public Companies and
Individual Investors